|
1
|
Bhanji RA, Carey EJ and Watt KD: Review
article: Maximising quality of life while aspiring for quantity of
life in end-stage liver disease. Aliment Pharmacol Ther. 46:16–25.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Marchesini G, Bianchi G, Amodio P, Salerno
F, Merli M, Panella C, Loguercio C, Apolone G, Niero M, et al:
Factors associated with poor health-related quality of life of
patients with cirrhosis. Gastroenterology. 120:170–178.
2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Studenic P, Radner H, Smolen JS and
Aletaha D: Discrepancies between patients and physicians in their
perceptions of rheumatoid arthritis disease activity. Arthritis
Rheum. 64:2814–2823. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Gutteling JJ, de Man RA, van der Plas SM,
Schalm SW, Busschbach JJ and Darlington AS: Determinants of quality
of life in chronic liver patients. Aliment Pharmacol Ther.
23:1629–1635. 2006.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Prinsen CA, Mokkink LB, Bouter LM, Alonso
J, Patrick DL, de Vet HC and Terwee CB: COSMIN guideline for
systematic reviews of patient-reported outcome measures. Qual Life
Res. 27:1147–1157. 2018.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cheung AC, Patel H, Meza-Cardona J, Cino
M, Sockalingam S and Hirschfield GM: Factors that influence
health-related quality of life in patients with primary Sclerosing
cholangitis. Dig Dis Sci. 61:1692–1699. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Klompenhouwer AJ, Sprengers D, Willemssen
FE, Gaspersz MP, Ijzermans JN and De Man RA: Evidence of good
prognosis of hepatocellular adenoma in post-menopausal women. J
Hepatol. 65:1163–1170. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Onishi Y, Wakita T, Fukuhara S, Noguchi Y,
Okada M, Sakaida I, Sasaki Y and Kobayashi K: Development and
validation of a symptom scale specific for ascites accompanied with
cirrhosis: The ASI-7. Clin Transl Gastroenterol.
5(e48)2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Schrier RW, Gross P, Gheorghiade M, Berl
T, Verbalis JG, Czerwiec FS and Orlandi C: SALT Investigators.
Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for
hyponatremia. N Engl J Med. 355:2099–2112. 2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Miyazaki T, Yamamura Y, Onogawa T,
Nakamura S, Kinoshita S, Nakayama S, Fujiki H and Mori T:
Therapeutic effects of tolvaptan, a potent, selective nonpeptide
vasopressin V2 receptor antagonist, in rats with acute and chronic
severe hyponatremia. Endocrinology. 146:3037–3043. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Sakaida I, Yanase M, Kobayashi Y, Yasutake
T, Okada M, Okita K, Kageyama F, Miyaoka H, Nakamura H, Sakaeda H,
et al: ASCITES Clinical Pharmacology Group: The pharmacokinetics
and pharmacodynamics of tolvaptan in patients with liver cirrhosis
with insufficient response to conventional diuretics: A
multicentre, double-blind, parallel-group, phase III study. J Int
Med Res. 40:2381–2393. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Yamamura Y, Nakamura S, Itoh S, Hirano T,
Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K,
et al: OPC-41061, a highly potent human vasopressin V2-receptor
antagonist: Pharmacological profile and aquaretic effect by single
and multiple oral dosing in rats. J Pharmacol Exp Ther.
287:860–867. 1998.PubMed/NCBI
|
|
13
|
Clark WF, Devuyst O and Roussel R: The
vasopressin system: new insights for patients with kidney diseases:
Epidemiological evidence and therapeutic perspectives. J Intern
Med. 282:310–321. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gülberg V, Liss I, Bilzer M, Waggershauser
T, Reiser M and Gerbes AL: Improved quality of life in patients
with refractory or recidivant ascites after insertion of
transjugular intrahepatic portosystemic shunts. Digestion.
66:127–130. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Neijenhuis M, Gevers TJG, Atwell TD,
Gunneson TJ, Schimek AC, Kievit W, Drenth JPH and Kamath PS:
Development and validation of a patient-reported outcome
measurement for symptom assessment in cirrhotic ascites. Am J
Gastroenterol. 113:567–575. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Vilstrup H, Amodio P, Bajaj J, Cordoba J,
Ferenci P, Mullen KD, Weissenborn K and Wong P: Hepatic
encephalopathy in chronic liver disease: 2014 Practice Guideline by
the American Association for the Study of Liver Diseases and the
European Association for the Study of the Liver. Hepatology.
60:715–735. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hiramine Y, Uojima H, Nakanishi H,
Hiramatsu A, Iwamoto T, Kimura M, Kawaratani H, Terai S, Yoshiji H,
Uto H, et al: Response criteria of tolvaptan for the treatment of
hepatic edema. J Gastroenterol. 53:258–268. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Pugh RN, Murray-Lyon IM, Dawson JL,
Pietroni MC and Williams R: Transection of the oesophagus for
bleeding oesophageal varices. Br J Surg. 60:646–649.
1973.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Moore KP, Wong F, Gines P, Bernardi M,
Ochs A, Salerno F, Angeli P, Porayko M, Moreau R, Garcia-Tsao G, et
al: The management of ascites in cirrhosis: Report on the consensus
conference of the International Ascites Club. Hepatology.
38:258–266. 2003.PubMed/NCBI View Article : Google Scholar
|
|
20
|
European Association for the Study of the
Liver. EASL clinical practice guidelines on the management of
ascites, spontaneous bacterial peritonitis, and hepatorenal
syndrome in cirrhosis. J Hepatol. 53:397–417. 2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Iwakiri Y, Shah V and Rockey DC: Vascular
pathobiology in chronic liver disease and cirrhosis - current
status and future directions. J Hepatol. 61:912–924.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Schrier RW: Water and sodium retention in
edematous disorders: Role of vasopressin and aldosterone. Am J Med.
119 (Suppl 1):S47–S53. 2006.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wong F: The use of TIPS in chronic liver
disease. Ann Hepatol. 5:5–15. 2006.PubMed/NCBI
|
|
24
|
Bureau C, Adebayo D, Chalret de Rieu M,
Elkrief L, Valla D, Peck-Radosavljevic M, McCune A, Vargas V,
Simon-Talero M, Cordoba J, et al: Alfapump® system vs.
large volume paracentesis for refractory ascites: A multicenter
randomized controlled study. J Hepatol. 67:940–949. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kawaratani H, Fukui H, Moriya K, Noguchi
R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, et
al: Predictive parameter of tolvaptan effectiveness in cirrhotic
ascites. Hepatol Res. 47:854–861. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kawaratani H, Fukui H and Yoshiji H:
Treatment for cirrhotic ascites. Hepatol Res. 47:166–177.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Fukuhara S, Bito S, Green J, Hsiao A and
Kurokawa K: Translation, adaptation, and validation of the SF-36
Health Survey for use in Japan. J Clin Epidemiol. 51:1037–1044.
1998.PubMed/NCBI View Article : Google Scholar
|
